Our Impact

Our Impact

Internationally, prevalence rates for HIV among injecting users are around 13%. In New Zealand, due largely to the early introduction of needle exchange and the work of the programme, prevalence rates are very low at 0.2%.

People injecting drugs are the most affected by hepatitis C with a national prevalence of 59%, and regional variance as high as 84%.

According to the 2013 Seroprevalence study, 69% of people injecting drugs report using a new needle every time.

Our aim is to ensure that people have access to sufficient new equipment for every injecting episode.